Each filer's latest filing for 207523101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Panacea Innovation Ltd
13D/A
|
25.1% |
7/21/2025
Event 7/21/2025
|
||
| Panacea Innovation Limited | 25.1% | |||
| Panacea Venture Healthcare Fund II, L.P. | 25.1% | |||
| Panacea Venture Healthcare Fund II GP Company, Ltd. | 25.1% | |||
| James Huang | 25.1% | |||
|
BioFortune Inc
13G
|
9.6% |
4/14/2026
Event 4/14/2026
|
||
| BioFortune Inc | 9.5% | |||
| Wubin Pan | 9.6% | |||
|
Ikarian Capital, LLC
13G/A
|
6.9% |
8/14/2026
Event 6/30/2026
|
||
| Ikarian Capital, LLC | 6.9% | |||
| Neil Shahrestani | 6.9% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||
| Wei Zheng 13G/A | 4.0% |
8/14/2026
Event 6/30/2026
|
||
| Period | Filers | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 22.2 k | $24.4k |
| 2026 Q2 | 1 | 42.3 k | $101k |
| 2026 Q1 | 1 | 1.25 k | $3.27k |
| 2025 Q4 | 1 | 1.29 k | $3.63k |
| 2025 Q3 | 1 | 1.58 k | $2.39k |
| 2025 Q2 | 18 | 2.44 M | $2.40M |
| 2025 Q1 | 14 | 2.83 M | $1.56M |
| 2024 Q4 | 16 | 3.18 M | $4.37M |
| 2024 Q3 | 12 | 2.94 M | $4.23M |
| 2024 Q2 | 14 | 2.98 M | $4.52M |
| 2024 Q1 | 14 | 3.95 M | $6.87M |
| 2023 Q4 | 16 | 7.12 M | $8.40M |
| 2023 Q3 | 15 | 10.1 M | $8.22M |
| 2023 Q2 | 17 | 10.4 M | $11.7M |
| 2023 Q1 | 17 | 10.9 M | $10.9M |
| 2022 Q4 | 22 | 11.6 M | $10.1M |
| 2022 Q3 | 26 | 12.7 M | $16.4M |
| 2022 Q2 | 30 | 15.0 M | $13.0M |
| 2022 Q1 | 30 | 17.7 M | $53.4M |
| 2021 Q4 | 30 | 17.0 M | $87.4M |
| 2021 Q3 | 21 | 19.4 M | $467M |
| 2021 Q2 | 17 | 19.1 M | $372M |
| 2021 Q1 | 27 | 15.4 M | $285M |